Rethinking the Rules of PMR
I'm Denise Peng, a premed student spending my gap year working as a medical assistant at Well By Messer. Last week, a lovely elderly gentleman came in for diabetes management. After reviewing his blood sugar levels, he mentioned he had been experiencing months of extreme fatigue and severe muscle pain.
The leading suspicion was polymyalgia rheumatica, or PMR, the most common inflammatory rheumatic disease in adults over 50. The classic presentation involves an abrupt onset of bilateral pain and profound morning stiffness in the shoulders, pelvic girdle, and thighs, sometimes accompanied by systemic symptoms like fatigue, low-grade fevers, and weight loss. This patient fit the profile closely.
Dr. Messer ordered labs. Because PMR is an inflammatory condition, its hallmark markers, erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), are almost always elevated. ESR reflects longer-term inflammatory activity, while CRP captures more acute inflammation..
The results came back normal. Dr. Messer ordered a second round. Normal again.
This was my introduction to the reality that medicine rarely moves in a straight line. Recent literature supports the instinct to pause here: normal ESR and CRP levels are generally considered to make PMR unlikely.
It is worth pausing on just how common this kind of presentation really is. Studies show that between 7% and 22% of PMR patients have a normal ESR at the time of diagnosis. In one study of 54 clinically diagnosed PMR patients, ESR and CRP values were normal in 14% of the group.
Because lab markers do not always cooperate, imaging has become an increasingly valuable part of the diagnostic workup. Ultrasound, MRI, and PET have emerged as the most promising imaging techniques for PMR.
Despite the lab results, the patient's clinical presentation remained convincingly classic: the distribution of pain, the stiffness, the timeline, all pointing in one direction. Dr. Messer ordered an ultrasound, which confirmed findings consistent with PMR. Those imaging results were then validated by MRI.
After starting steroids, the patient felt dramatically better, the pain that had been limiting him for months now largely resolved. PMR treatment typically reduces pain by up to 70% within the first month in up to 96% of patients. That response, paired with the clinical picture and imaging findings, confirmed the diagnosis: sero-negative PMR, presenting without the expected inflammatory markers.
Watching Dr. Messer work through that process and seeing it pay off for the patient was one of the more memorable moments of my gap year so far.
Patients with normal ESR and CRP tend to experience a milder overall disease course and a shorter time to glucocorticoid-free remission compared to those with elevated markers. They do, however, tend to face a longer road to diagnosis, averaging around 13 weeks compared to 10 weeks for those with abnormal labs. The core symptoms remain the same across both groups: that characteristic stiffness and pain in the hips and shoulders, present regardless of what the bloodwork shows.
For me, this case was an early reminder that good clinical reasoning is not about waiting for perfect data. It is about knowing how to weigh imperfect data thoughtfully. I came into this gap year hoping to learn the basics. It turns out the basics are more layered than I expected, and I am grateful to be learning them in a setting where I get to watch that process up close.